Phaseline

Targets › IL33R

IL33R: drug programs, companies and trials

1 program from 1 company in 2 trials: 2 Phase 3; Respiratory; next expected readout Jun 2027.

Open in Phaseline: the race on IL33R, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
RocheAstegolimab
IL-33 receptor (ST2) inhibitor
IL1RAP, IL33RPhase 3Chronic Obstructive Pulmonary Disease (COPD); Chronic Obstructive Pulmonary DiseaseJun 2027

Conditions

Chronic Obstructive Pulmonary Disease (COPD) (1) Chronic Obstructive Pulmonary Disease (1)

Modalities

antibody (1)

Companies

Roche (1)

Related targets

IL1RAP (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.